Gilead Sciences, Inc. (NASDAQ:GILD) Position Cut by Prudential PLC

Prudential PLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 257,663 shares of the biopharmaceutical company's stock after selling 23,341 shares during the quarter. Prudential PLC's holdings in Gilead Sciences were worth $23,800,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Bank of America upped their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Morgan Stanley raised their price objective on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a report on Tuesday, March 11th. Finally, Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $105.12.

Remove Ads

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last quarter. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 2.7 %

Shares of Gilead Sciences stock traded down $2.89 on Monday, hitting $104.37. 5,683,780 shares of the company's stock traded hands, compared to its average volume of 8,648,900. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market cap of $129.95 billion, a P/E ratio of 282.07, a PEG ratio of 0.71 and a beta of 0.32. The firm's 50-day moving average is $107.30 and its 200 day moving average is $95.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.03%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.